Journal of Clinical Oncology, Vol 12, 553-559, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

H Hochster, L Liebes, J Speyer, J Sorich, B Taubes, R Oratz, J Wernz, A Chachoua, B Raphael and RZ Vinci
Kaplan Comprehensive Cancer Center, Division of Medical Oncology, New York University Medical Center, New York 10016.

PURPOSE: The objective of this trial was to define the maximum- tolerated dose (MTD) of topotecan for a 21-day infusion schedule, repeated every 28 days, in patients with cancer. PATIENTS AND METHODS: Cohorts of four patients received continuous ambulatory infusions of topotecan in escalated duration with doses beginning at 0.20 mg/m2/d for 7 days. Forty-four patients with a histologic diagnosis of cancer refractory to standard therapy were treated with infusions of topotecan for a total of 115 cycles and 1,780 patient-days of infusion. The median number of treatment cycles per patient was two (range, one to eight). All patients were heavily pretreated with chemotherapy and/or radiation. RESULTS: The dose-limiting toxicity (DLT) was myelo- suppression, with thrombocytopenia greater than neutropenia seen at the dose level of 0.70 mg/m2/d for 21 days. At the MTD of 0.53 mg/m2, ten patients were treated for a total of 20 courses, resulting in one episode of grade 4 thrombocytopenia and leukopenia, one grade 3 thrombocytopenia, and two grade 3 leukopenias. This dose regimen was well tolerated, with minimal nonhematologic toxicity. Local infusion port complications developed in two patients and two had bacteremia, including one patient with repeated local skin infections. Objective responses were observed in this heavily pretreated population for patients with ovarian cancer (two partial responses and one mixed response in six patients), breast cancer (one partial response and one mixed response in two patients), and for one patient each with renal and non-small-cell lung cancer (two partial remissions). CONCLUSION: Twenty-one-day topotecan infusion is well tolerated at 0.53 mg/m2, with dose-intensity exceeding other schedules for administration of topotecan. The DLT is hematologic, with thrombocytopenia somewhat exceeding leukopenia. Objective responses were observed in seven patients with breast, ovarian, renal, and non-small-cell lung cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. E.L.M. Kuppens, E. O. Witteveen, R. C. Jewell, S. A. Radema, E. M. Paul, S. G. Mangum, J. H. Beijnen, E. E. Voest, and J. H.M. Schellens A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients Clin. Cancer Res., June 1, 2007; 13(11): 3276 - 3285. [Abstract] [Full Text] [PDF]

				F. Muggia, R. Kosloff, L. Liebes, and H. Hochster Topotecan Continuous Infusion: CA-125 Responses Including Patients Pretreated with Other Schedules of Topotecan. Oncologist, May 1, 2006; 11(5): 529 - 531. [Full Text] [PDF]

				D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919. [Abstract] [Full Text] [PDF]

				N. C. Daw, V. M. Santana, L. C. Iacono, W. L. Furman, D. R. Hawkins, P. J. Houghton, J. C. Panetta, A. J. Gajjar, and C. F. Stewart Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., March 1, 2004; 22(5): 829 - 837. [Abstract] [Full Text] [PDF]

				M. A. Garrison, L. A. Hammond, C. E. Geyer Jr., G. Schwartz, A. W. Tolcher, L. Smetzer, J. A. Figueroa, M. Ducharme, J. Coyle, C. H. Takimoto, et al. A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies Clin. Cancer Res., July 1, 2003; 9(7): 2527 - 2537. [Abstract] [Full Text] [PDF]

				S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink, and G. Goldberg Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93 J. Clin. Oncol., June 1, 2003; 21(11): 2110 - 2114. [Abstract] [Full Text] [PDF]

				S. N. Sanghavi, M. N. Needle, M. D. Krailo, J. R. Geyer, J. Ater, and M. P. Mehta A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952 Neuro-oncol, January 1, 2003; 5(1): 8 - 13. [Abstract] [PDF]

				R. Morris and A. Munkarah Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 29 - 35. [Abstract] [Full Text] [PDF]

				C. M.F. Kruijtzer, J. H. Beijnen, H. Rosing, W. W. ten Bokkel Huinink, M. Schot, R. C. Jewell, E. M. Paul, and J. H.M. Schellens Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918 J. Clin. Oncol., July 1, 2002; 20(13): 2943 - 2950. [Abstract] [Full Text] [PDF]

				Z. Han, W. Wei, S. Dunaway, J. W. Darnowski, P. Calabresi, J. Sedivy, E. A. Hendrickson, K. V. Balan, P. Pantazis, and J. H. Wyche Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin J. Biol. Chem., May 3, 2002; 277(19): 17154 - 17160. [Abstract] [Full Text] [PDF]

				W. L. Furman, C. F. Stewart, M. Kirstein, J. L. Kepner, M. L. Bernstein, F. Kung, T. J. Vietti, C. P. Steuber, D. L. Becton, S. Baruchel, et al. Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 15, 2002; 20(6): 1617 - 1624. [Abstract] [Full Text] [PDF]

				S. Guichard, A. Montazeri, E. Chatelut, I. Hennebelle, R. Bugat, and P. Canal Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation Clin. Cancer Res., October 1, 2001; 7(10): 3222 - 3228. [Abstract] [Full Text] [PDF]

				B. Ng, E. Kramer, L. Liebes, C. Wasserheit, H. Hochster, E. Blank, R. Ceriani, and P. Furmanski Radiosensitization of Tumor-targeted Radioimmunotherapy with Prolonged Topotecan Infusion in Human Breast Cancer Xenografts Cancer Res., April 1, 2001; 61(7): 2996 - 3001. [Abstract] [Full Text]

				D. L. Emerson, R. Bendele, E. Brown, S. Chiang, J. P. Desjardins, L. C. Dihel, S. C. Gill, M. Hamilton, J. D. LeRay, L. Moon-McDermott, et al. Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan Clin. Cancer Res., July 1, 2000; 6(7): 2903 - 2912. [Abstract] [Full Text]

				H. Frangoul, M. M. Ames, R. B. Mosher, J. M. Reid, M. D. Krailo, N. L. Seibel, D. W. W. Shaw, P. G. Steinherz, J. A. Whitlock, and J. S. Holcenberg Phase I Study of Topotecan Administered as a 21-Day Continuous Infusion in Children with Recurrent Solid Tumors: A Report from the Children's Cancer Group Clin. Cancer Res., December 1, 1999; 5(12): 3956 - 3962. [Abstract] [Full Text] [PDF]

				H. Hochster, S. Wadler, C. Runowicz, L. Liebes, H. Cohen, R. Wallach, J. Sorich, B. Taubes, and J. Speyer Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy J. Clin. Oncol., August 1, 1999; 17(8): 2553 - 2553. [Abstract] [Full Text] [PDF]

				M. J.A. de Jonge, C. J.A. Punt, A. H. Gelderblom, W. J. Loos, V. van Beurden, A. S.Th. Planting, M. E.L. van der Burg, L. W.G.M. van Maanen, B. K. Dallaire, J. Verweij, et al. Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors J. Clin. Oncol., July 1, 1999; 17(7): 2219 - 2219. [Abstract] [Full Text] [PDF]

				V. M.M. Herben, R. van Gijn, J. H.M. Schellens, M. Schot, J. Lieverst, M. J.X. Hillebrand, N. E. Schoemaker, M. G. Porro, J. H. Beijnen, and W. W. ten Bokkel Huinink Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors J. Clin. Oncol., June 1, 1999; 17(6): 1906 - 1906. [Abstract] [Full Text] [PDF]

				C. J. H. Gerrits, J. H. M. Schellens, H. Burris, J. R. Eckardt, A. S. T. Planting, M. E. L. van der Burg, G. I. Rodriguez, W. J. Loos, V. van Beurden, I. Hudson, et al. A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin) Clin. Cancer Res., January 1, 1999; 5(1): 69 - 75. [Abstract] [Full Text] [PDF]

				J. J. O'Leary, R. L. Shapiro, C. J. Ren, N. Chuang, H. W. Cohen, and M. Potmesil Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20(S)-camptothecin, Topotecan, and CPT-11 Studied in the Mouse Cornea Model Clin. Cancer Res., January 1, 1999; 5(1): 181 - 187. [Abstract] [Full Text] [PDF]

				J.-F. Héron Topotecan: An Oncologist's View Oncologist, December 1, 1998; 3(6): 390 - 402. [Abstract] [Full Text]

				V. Relias and J. Andrew Skirvin Review : Topoisomerase I inhibitors: 1. Topotecan Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 173 - 185. [Abstract] [PDF]